Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy

INTRODUCTION: Anti-PD-(L)1 immune checkpoint inhibitors (ICI) improve survival in patients with advanced non-small cell lung cancer (aNSCLC). The clinical features, survival, and burden of toxicities of patients with aNSCLC alive >1 year from ICI initiation are poorly understood. MATERIALS AND ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Melinda L, Murray, Joseph C, Psoter, Kevin J, Zhang, Jiajia, Barasa, Durrant, Brahmer, Julie R, Ettinger, David S, Forde, Patrick M, Hann, Christine L, Lam, Vincent K, Levy, Benjamin, Marrone, Kristen A, Patel, Tricia, Peterson, Valerie, Sagorsky, Sarah, Turner, Michelle, Anagnostou, Valsamo, Naidoo, Jarushka, Feliciano, Josephine L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632301/
https://www.ncbi.nlm.nih.gov/pubmed/35972337
http://dx.doi.org/10.1093/oncolo/oyac140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632301/
https://www.ncbi.nlm.nih.gov/pubmed/35972337
http://dx.doi.org/10.1093/oncolo/oyac140

Ejemplares similares